{"protocolSection":{"identificationModule":{"nctId":"NCT00206063","orgStudyIdInfo":{"id":"SH-TPA-0004"},"secondaryIdInfos":[{"id":"D4004C00004"}],"organization":{"fullName":"AstraZeneca","class":"INDUSTRY"},"briefTitle":"Long Term Open Follow-up With H376/95 vs. Warfarin","officialTitle":"Long-Term Treatment With the Oral Direct Thrombin Inhibitor Ximelagatran, Compared to Warfarin, as Stroke Prophylaxis in Patients With Atrial Fibrillation. A Long Term Follow-Up Study"},"statusModule":{"statusVerifiedDate":"2010-11","overallStatus":"TERMINATED","whyStopped":"Melagatran/ximelagatran was withdrawn from the market and clinical development in February 2006 in the interest of patient safety.","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"1999-08"},"primaryCompletionDateStruct":{"date":"2004-06","type":"ACTUAL"},"completionDateStruct":{"date":"2006-04","type":"ACTUAL"},"studyFirstSubmitDate":"2005-09-13","studyFirstSubmitQcDate":"2005-09-13","studyFirstPostDateStruct":{"date":"2005-09-21","type":"ESTIMATED"},"lastUpdateSubmitDate":"2010-11-10","lastUpdatePostDateStruct":{"date":"2010-11-15","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca","class":"INDUSTRY"}},"descriptionModule":{"briefSummary":"The purpose of this study is to evaluate tolerability of long-term treatment with ximelagatran compared to standard treatment with warfarin."},"conditionsModule":{"conditions":["Stroke Prevention in Patients With Atrial Fibrillation"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":220}},"armsInterventionsModule":{"interventions":[{"type":"DRUG","name":"EXANTA","otherNames":["Ximelagatran"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Number of Adverse Events, with special regard to bleeding, thromboembolic events and discontinuation of treatment."}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Signed informed consent.\n* Completion of the study SH-TPA-0002, history of chronic atrial fibrillation (i.e. rapidly beating heart), at least one risk factor for stroke (e.g. high blood pressure, age over 65, previous stroke or similar attack, diabetes or coronary heart disease)\n\nExclusion Criteria:\n\n* Conditions associated with increased risk of bleeding, renal impairment, known active liver disease or liver insufficiency","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"locations":[{"facility":"Research Site","city":"Palo Alto","state":"California","country":"United States","geoPoint":{"lat":37.44188,"lon":-122.14302}},{"facility":"Research Site","city":"Oostduinkerke","country":"Belgium","geoPoint":{"lat":51.11565,"lon":2.68217}},{"facility":"Research Site","city":"Helsingor","country":"Czech Republic"},{"facility":"Research Site","city":"Most","country":"Czech Republic","geoPoint":{"lat":50.50301,"lon":13.63617}},{"facility":"Research Site","city":"Plzeo","country":"Czech Republic"},{"facility":"Research Site","city":"Poibram","country":"Czech Republic"},{"facility":"Research Site","city":"Prague","country":"Czech Republic","geoPoint":{"lat":50.08804,"lon":14.42076}},{"facility":"Research Site","city":"Arhus","country":"Denmark","geoPoint":{"lat":56.15674,"lon":10.21076}},{"facility":"Research Site","city":"Odense","country":"Denmark","geoPoint":{"lat":55.39594,"lon":10.38831}},{"facility":"Research Site","city":"Kuopio","country":"Finland","geoPoint":{"lat":62.89238,"lon":27.67703}},{"facility":"Research Site","city":"Savonlinna","country":"Finland","geoPoint":{"lat":61.8699,"lon":28.87999}},{"facility":"Research Site","city":"Hamar","country":"Norway","geoPoint":{"lat":60.7945,"lon":11.06798}},{"facility":"Research Site","city":"Oslo","country":"Norway","geoPoint":{"lat":59.91273,"lon":10.74609}},{"facility":"Research Site","city":"Plock","country":"Poland","geoPoint":{"lat":52.54682,"lon":19.70638}},{"facility":"Research Site","city":"Siedice","country":"Poland"},{"facility":"Research Site","city":"Warsaw","country":"Poland","geoPoint":{"lat":52.22977,"lon":21.01178}},{"facility":"Research Site","city":"Lund","country":"Sweden","geoPoint":{"lat":55.70584,"lon":13.19321}},{"facility":"Research Site","city":"Leicester","country":"United Kingdom","geoPoint":{"lat":52.6386,"lon":-1.13169}},{"facility":"Research Site","city":"Newcastle","country":"United Kingdom","geoPoint":{"lat":54.97328,"lon":-1.61396}}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000001281","term":"Atrial Fibrillation"}],"ancestors":[{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000001145","term":"Arrhythmias, Cardiac"},{"id":"D000006331","term":"Heart Diseases"},{"id":"D000010335","term":"Pathologic Processes"}],"browseLeaves":[{"id":"M21996","name":"Stroke","relevance":"LOW"},{"id":"M4276","name":"Atrial Fibrillation","asFound":"Atrial Fibrillation","relevance":"HIGH"},{"id":"M4143","name":"Arrhythmias, Cardiac","relevance":"LOW"},{"id":"M9109","name":"Heart Diseases","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"}]},"interventionBrowseModule":{"meshes":[{"id":"C000426686","term":"Ximelagatran"}],"ancestors":[{"id":"D000000991","term":"Antithrombins"},{"id":"D000015842","term":"Serine Proteinase Inhibitors"},{"id":"D000011480","term":"Protease Inhibitors"},{"id":"D000004791","term":"Enzyme Inhibitors"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000000925","term":"Anticoagulants"}],"browseLeaves":[{"id":"M16366","name":"Thrombin","relevance":"LOW"},{"id":"M17292","name":"Warfarin","relevance":"LOW"},{"id":"M3997","name":"Antithrombins","relevance":"LOW"},{"id":"M213351","name":"Ximelagatran","asFound":"Tissue factor pathway inhibitor","relevance":"HIGH"},{"id":"M3996","name":"Antithrombin III","relevance":"LOW"},{"id":"M14033","name":"Protease Inhibitors","relevance":"LOW"},{"id":"M18081","name":"Serine Proteinase Inhibitors","relevance":"LOW"},{"id":"M19299","name":"HIV Protease Inhibitors","relevance":"LOW"},{"id":"M7641","name":"Enzyme Inhibitors","relevance":"LOW"},{"id":"M3934","name":"Anticoagulants","relevance":"LOW"},{"id":"T18","name":"Serine","relevance":"LOW"}],"browseBranches":[{"abbrev":"Coag","name":"Coagulants"},{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"AnCoag","name":"Anticoagulants"},{"abbrev":"Infe","name":"Anti-Infective Agents"},{"abbrev":"AA","name":"Amino Acids"}]}},"hasResults":false}